Abu Dhabi, UAE – Abu Dhabi Biobank, the joint strategic initiative between the Department of Health – Abu Dhabi and M42 Group, signed a cooperation agreement with «AstraZeneca».
This is with the aim of developing the fields of precision medicine and transforming the results of clinical research into practical therapeutic applications.
This cooperation combines the advanced infrastructure of Abu Dhabi Biobank in the fields of biological sample preservation and genomics, with the global scientific expertise of the company «AstraZeneca» in the fields of treating cardiovascular diseases, kidney, metabolism, respiratory system, immunity and tumors.
Through this cooperation, the two parties seek to transform complex biological data analyses into realistic therapeutic solutions that contribute to enhancing quality of life.
The two parties will cooperate across multiple strategic axes, benefiting from Abu Dhabi Biobank’s huge biological sample base, its extensive research data and advanced infrastructure.
Areas of cooperation will include developing clinical research and precision medicine, and generating evidence based on real practice.
This contributes to accelerating the discovery of biomarkers, genetic-pharmacological analysis, and the classification of precise disease groups.
The cooperation supports the fields of health economics and health regulatory sciences.
Along with emerging fields, such as digital health and artificial intelligence, to enable data-driven health systems.
This cooperation is a major milestone in Abu Dhabi’s ambitions to transform into a global center for biomedical research and innovation in life sciences.
This collaboration contributes to accelerating the transition from scientific research to regulatory approvals and clinical applications.
This is done by utilizing long-term population data and population-specific analyses.
